Biodexa Pharmaceuticals PLCNASDAQ:BDRX
- LAST PRICE0.7248
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.7248/ 2
- Ask / Lots0.9880/ 1
- Open / Previous Close0.0000 / 0.7248
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BDRX |
|---|---|---|
| 09:32 ET | 1113 | 0.74 |
| 09:34 ET | 119 | 0.73 |
| 09:36 ET | 4947 | 0.72 |
| 09:39 ET | 34850 | 0.6711 |
| 09:41 ET | 100 | 0.7 |
| 09:43 ET | 150 | 0.7 |
| 09:48 ET | 2200 | 0.7344 |
| 09:56 ET | 720 | 0.7 |
| 09:57 ET | 12921 | 0.69999 |
| 10:01 ET | 8993 | 0.6999 |
| 10:03 ET | 100 | 0.6999 |
| 10:06 ET | 1142 | 0.6999 |
| 10:08 ET | 200 | 0.6999 |
| 10:15 ET | 400 | 0.6999 |
| 10:17 ET | 400 | 0.6999 |
| 10:19 ET | 100 | 0.7 |
| 10:21 ET | 1000 | 0.6999 |
| 10:24 ET | 400 | 0.697 |
| 10:32 ET | 100 | 0.697 |
| 10:35 ET | 100 | 0.69 |
| 10:39 ET | 300 | 0.6987 |
| 10:46 ET | 150 | 0.6988 |
| 10:51 ET | 200 | 0.6988 |
| 10:55 ET | 150 | 0.69 |
| 10:57 ET | 1100 | 0.69495 |
| 11:04 ET | 380 | 0.6975 |
| 11:13 ET | 143 | 0.6951 |
| 11:15 ET | 300 | 0.69 |
| 11:26 ET | 1171 | 0.69 |
| 11:29 ET | 100 | 0.7 |
| 11:51 ET | 120 | 0.6999 |
| 11:54 ET | 357 | 0.6801 |
| 12:12 ET | 800 | 0.6853 |
| 12:14 ET | 100 | 0.6853 |
| 12:45 ET | 747 | 0.6821 |
| 12:57 ET | 700 | 0.7 |
| 01:01 ET | 2000 | 0.699899 |
| 01:08 ET | 302 | 0.6981 |
| 01:26 ET | 325 | 0.6999 |
| 01:32 ET | 107 | 0.69 |
| 01:33 ET | 300 | 0.6993 |
| 01:57 ET | 113 | 0.6949 |
| 02:02 ET | 100 | 0.69 |
| 02:06 ET | 400 | 0.6996 |
| 02:13 ET | 12485 | 0.701 |
| 02:15 ET | 5200 | 0.7175 |
| 02:26 ET | 1000 | 0.715 |
| 03:05 ET | 8350 | 0.7 |
| 03:14 ET | 100 | 0.7 |
| 03:38 ET | 900 | 0.715 |
| 03:45 ET | 132 | 0.715 |
| 03:50 ET | 1000 | 0.715 |
| 03:59 ET | 11688 | 0.72 |
Apr 19, 2024
Preliminary Results for the Year Ended 31 December 2023, from 8:00AM ET on Friday Apr 19, 2024 by Dow Jones
8:00AM ET on Friday Apr 19, 2024 by Dow Jones
Mar 28, 2024
Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers, from 8:17AM ET on Thursday Mar 28, 2024 by Dow Jones
8:17AM ET on Thursday Mar 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Biodexa Pharmaceuticals PLC | 3.2M | 0.0x | --- |
Aditxt Inc | 4.2M | 0.0x | --- |
Lipella Pharmaceuticals Inc | 4.8M | -0.9x | --- |
Manuka Inc | 4.5M | -3.1x | --- |
Marizyme Inc | 4.4M | -0.1x | --- |
Cyclacel Pharmaceuticals Inc | 2.1M | -0.1x | --- |
Company Information
Biodexa Pharmaceuticals PLC is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. The MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility biological potential of Hydrogen (pH), extending available routes of administration, including direct-to-tumor delivery. Its pipeline includes MTX110, MTD201, MTD211 (Schizophrenia, MDD), MTX223, and MTD217.
Contact Information
- Headquarters
- 1 Caspian Point, Caspian WayABINGDON, United Kingdom CF10 4DQ
- Phone
- 123-584-1575
- Fax
- ---
Executives
- Non-Executive Chairman of the Board
- Stephen Parker
- Chief Executive Officer, Chief Financial Officer, Executive Director, Secretary
- Stephen Stamp
- Chief Scientific Officer
- Dmitry Zamoryakhin
- Vice President - Head of Clinical Operations
- Vincent Holmes
- Vice President - Technology
- Daniel Palmer
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.2M |
|---|---|
Revenue (TTM) | $476.7K |
Shares Outstanding | 11.0K |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.68 |
EPS | $-366.95 |
Book Value | $0.79 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 6.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,103.41% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
